No Data
No Data
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
Milestone Pharmaceuticals' Strong Buy Rating: CARDAMYST's FDA Resubmission and Bright Revenue Prospects
Express News | Milestone Pharmaceuticals Says Cash Resources As Of March 31, 2024 Of $89.5M Is Expected To Fund Operations Into 2026
Express News | Milestone Pharmaceuticals Q1 2024 GAAP EPS $(0.21) Beats $(0.24) Estimate
Express News | Milestone Pharmaceuticals Inc: Cash Resources as of March 31, 2024 Expected to Fund Operations Into 2026
Express News | Milestone Pharmaceuticals Q1 Income From Operations USD -10.476 Million